Impact of TKI Switching, Reduction, and Discontinuation on Cardiovascular Events in cml patients Article Swipe
Nobue Sato
,
Yong‐Mei Guo
,
Hirotaka Nakamura
,
Satoshi Uchiyama
,
Kodai Kunisada
,
Song‐Gi Chi
,
Akihito Nagata
,
Nobuhiko Yamauchi
,
Hiraku Ogata
,
Yosuke Minami
,
Junichiro Yuda
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.21203/rs.3.rs-3632503/v1
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.21203/rs.3.rs-3632503/v1
The development of tyrosine kinase inhibitors (TKIs) has dramatically improved the treatment outcomes of the chronic myelogenous leukemia-chronic phase (CML-CP). However, cardiovascular events (CVEs), such as hypertension, peripheral arterial occlusive disease, pulmonary arterial hypertension, and cerebral infarction, continue to occur, which highlights the need to develop preventive monitoring and treatment strategy for adverse vascular events. This study retrospectively analyzed the data on CVEs in 63 patients with chronic myeloid leukemia treated with TKIs at our institution. TKI treatments were discontinued in 1 patient and 16 patients owing to serious CVEs and adverse events other than CVEs, respectively. This study showed that male patients tended to experience more abnormal findings on cardiovascular examination and minor CVEs with increasing age than female patients. No prolongation of QT interval was observed. During follow-up, improvements in tricuspid regurgitant pressure gradient and brain natriuretic peptide values and hypertension were observed after reducing the dose of the same TKI, interrupting the TKI treatment, and switching from the second-and third-generation TKIs to imatinib (IM) or bosutinib (BOS). These data suggest the importance of CVE prevention via blood pressure control and cardiovascular examination in CML patients at high risk for CVE. Rapid intervention under the cooperation of a cardiologist is also essential when CVEs develop. The CVE risk may be decreased by switching to IM or BOS or via TKI dose reduction/interruption in patients in whom DMR is achieved. However, further studies with more patients are required.
Related Topics
Concepts
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.21203/rs.3.rs-3632503/v1
- https://www.researchsquare.com/article/rs-3632503/latest.pdf
- OA Status
- green
- References
- 30
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4389002321
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4389002321Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.21203/rs.3.rs-3632503/v1Digital Object Identifier
- Title
-
Impact of TKI Switching, Reduction, and Discontinuation on Cardiovascular Events in cml patientsWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-11-26Full publication date if available
- Authors
-
Nobue Sato, Yong‐Mei Guo, Hirotaka Nakamura, Satoshi Uchiyama, Kodai Kunisada, Song‐Gi Chi, Akihito Nagata, Nobuhiko Yamauchi, Hiraku Ogata, Yosuke Minami, Junichiro YudaList of authors in order
- Landing page
-
https://doi.org/10.21203/rs.3.rs-3632503/v1Publisher landing page
- PDF URL
-
https://www.researchsquare.com/article/rs-3632503/latest.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://www.researchsquare.com/article/rs-3632503/latest.pdfDirect OA link when available
- Concepts
-
Medicine, Discontinuation, Internal medicine, Cardiology, Bosutinib, Adverse effect, Chronic myelogenous leukemia, Myocardial infarction, Imatinib, Myeloid leukemia, Nilotinib, LeukemiaTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
30Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4389002321 |
|---|---|
| doi | https://doi.org/10.21203/rs.3.rs-3632503/v1 |
| ids.doi | https://doi.org/10.21203/rs.3.rs-3632503/v1 |
| ids.openalex | https://openalex.org/W4389002321 |
| fwci | 0.0 |
| type | preprint |
| title | Impact of TKI Switching, Reduction, and Discontinuation on Cardiovascular Events in cml patients |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T11535 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9973999857902527 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2705 |
| topics[0].subfield.display_name | Cardiology and Cardiovascular Medicine |
| topics[0].display_name | Chemotherapy-induced cardiotoxicity and mitigation |
| topics[1].id | https://openalex.org/T11215 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9943000078201294 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2720 |
| topics[1].subfield.display_name | Hematology |
| topics[1].display_name | Chronic Myeloid Leukemia Treatments |
| topics[2].id | https://openalex.org/T12876 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9232000112533569 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2740 |
| topics[2].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[2].display_name | Potassium and Related Disorders |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.931079626083374 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2778715236 |
| concepts[1].level | 2 |
| concepts[1].score | 0.7160378694534302 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q55622662 |
| concepts[1].display_name | Discontinuation |
| concepts[2].id | https://openalex.org/C126322002 |
| concepts[2].level | 1 |
| concepts[2].score | 0.6175847053527832 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[2].display_name | Internal medicine |
| concepts[3].id | https://openalex.org/C164705383 |
| concepts[3].level | 1 |
| concepts[3].score | 0.5249476432800293 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q10379 |
| concepts[3].display_name | Cardiology |
| concepts[4].id | https://openalex.org/C2778208673 |
| concepts[4].level | 5 |
| concepts[4].score | 0.5098442435264587 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q894611 |
| concepts[4].display_name | Bosutinib |
| concepts[5].id | https://openalex.org/C197934379 |
| concepts[5].level | 2 |
| concepts[5].score | 0.4614843726158142 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2047938 |
| concepts[5].display_name | Adverse effect |
| concepts[6].id | https://openalex.org/C2776960273 |
| concepts[6].level | 3 |
| concepts[6].score | 0.41465601325035095 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q729735 |
| concepts[6].display_name | Chronic myelogenous leukemia |
| concepts[7].id | https://openalex.org/C500558357 |
| concepts[7].level | 2 |
| concepts[7].score | 0.41345587372779846 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q12152 |
| concepts[7].display_name | Myocardial infarction |
| concepts[8].id | https://openalex.org/C2777583451 |
| concepts[8].level | 3 |
| concepts[8].score | 0.37264299392700195 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q177094 |
| concepts[8].display_name | Imatinib |
| concepts[9].id | https://openalex.org/C2778729363 |
| concepts[9].level | 2 |
| concepts[9].score | 0.2698221206665039 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q11688946 |
| concepts[9].display_name | Myeloid leukemia |
| concepts[10].id | https://openalex.org/C2777413986 |
| concepts[10].level | 4 |
| concepts[10].score | 0.17874464392662048 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q412327 |
| concepts[10].display_name | Nilotinib |
| concepts[11].id | https://openalex.org/C2778461978 |
| concepts[11].level | 2 |
| concepts[11].score | 0.16539251804351807 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q29496 |
| concepts[11].display_name | Leukemia |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.931079626083374 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/discontinuation |
| keywords[1].score | 0.7160378694534302 |
| keywords[1].display_name | Discontinuation |
| keywords[2].id | https://openalex.org/keywords/internal-medicine |
| keywords[2].score | 0.6175847053527832 |
| keywords[2].display_name | Internal medicine |
| keywords[3].id | https://openalex.org/keywords/cardiology |
| keywords[3].score | 0.5249476432800293 |
| keywords[3].display_name | Cardiology |
| keywords[4].id | https://openalex.org/keywords/bosutinib |
| keywords[4].score | 0.5098442435264587 |
| keywords[4].display_name | Bosutinib |
| keywords[5].id | https://openalex.org/keywords/adverse-effect |
| keywords[5].score | 0.4614843726158142 |
| keywords[5].display_name | Adverse effect |
| keywords[6].id | https://openalex.org/keywords/chronic-myelogenous-leukemia |
| keywords[6].score | 0.41465601325035095 |
| keywords[6].display_name | Chronic myelogenous leukemia |
| keywords[7].id | https://openalex.org/keywords/myocardial-infarction |
| keywords[7].score | 0.41345587372779846 |
| keywords[7].display_name | Myocardial infarction |
| keywords[8].id | https://openalex.org/keywords/imatinib |
| keywords[8].score | 0.37264299392700195 |
| keywords[8].display_name | Imatinib |
| keywords[9].id | https://openalex.org/keywords/myeloid-leukemia |
| keywords[9].score | 0.2698221206665039 |
| keywords[9].display_name | Myeloid leukemia |
| keywords[10].id | https://openalex.org/keywords/nilotinib |
| keywords[10].score | 0.17874464392662048 |
| keywords[10].display_name | Nilotinib |
| keywords[11].id | https://openalex.org/keywords/leukemia |
| keywords[11].score | 0.16539251804351807 |
| keywords[11].display_name | Leukemia |
| language | en |
| locations[0].id | doi:10.21203/rs.3.rs-3632503/v1 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4306402450 |
| locations[0].source.issn | |
| locations[0].source.type | repository |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | |
| locations[0].source.is_core | False |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Research Square (Research Square) |
| locations[0].source.host_organization | https://openalex.org/I4210096694 |
| locations[0].source.host_organization_name | Research Square (United States) |
| locations[0].source.host_organization_lineage | https://openalex.org/I4210096694 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.researchsquare.com/article/rs-3632503/latest.pdf |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.21203/rs.3.rs-3632503/v1 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5043644551 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Nobue Sato |
| authorships[0].countries | JP |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210145079 |
| authorships[0].affiliations[0].raw_affiliation_string | National Cancer Center Hospital East Yong-Mei Guo National Cancer Center Hospital East Hirotaka Nakamura National Cancer Center Hospital East Satoshi Uchiyama National Cancer Center Hospital East Kodai Kunisada National Cancer Center Hospital East Song-Gi Chi National Cancer Center Hospital East |
| authorships[0].affiliations[1].institution_ids | https://openalex.org/I4210145079 |
| authorships[0].affiliations[1].raw_affiliation_string | National Cancer Center Hospital East Nobuhiko Yamauchi National Cancer Center Hospital East Hiraku Ogata National Cancer Center Hospital East Yosuke Minami National Cancer Center Hospital East Junichiro Yuda |
| authorships[0].affiliations[2].institution_ids | https://openalex.org/I4210145079 |
| authorships[0].affiliations[2].raw_affiliation_string | National Cancer Center Hospital East |
| authorships[0].institutions[0].id | https://openalex.org/I4210145079 |
| authorships[0].institutions[0].ror | https://ror.org/03rm3gk43 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210145079 |
| authorships[0].institutions[0].country_code | JP |
| authorships[0].institutions[0].display_name | National Cancer Center Hospital East |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Nobue Sato |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | National Cancer Center Hospital East, National Cancer Center Hospital East Nobuhiko Yamauchi National Cancer Center Hospital East Hiraku Ogata National Cancer Center Hospital East Yosuke Minami National Cancer Center Hospital East Junichiro Yuda, National Cancer Center Hospital East Yong-Mei Guo National Cancer Center Hospital East Hirotaka Nakamura National Cancer Center Hospital East Satoshi Uchiyama National Cancer Center Hospital East Kodai Kunisada National Cancer Center Hospital East Song-Gi Chi National Cancer Center Hospital East |
| authorships[1].author.id | https://openalex.org/A5061708111 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-1563-727X |
| authorships[1].author.display_name | Yong‐Mei Guo |
| authorships[1].countries | JP |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210145079 |
| authorships[1].affiliations[0].raw_affiliation_string | National Cancer Center Hospital East |
| authorships[1].institutions[0].id | https://openalex.org/I4210145079 |
| authorships[1].institutions[0].ror | https://ror.org/03rm3gk43 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210145079 |
| authorships[1].institutions[0].country_code | JP |
| authorships[1].institutions[0].display_name | National Cancer Center Hospital East |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Yong-Mei Guo |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | National Cancer Center Hospital East |
| authorships[2].author.id | https://openalex.org/A5041246296 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Hirotaka Nakamura |
| authorships[2].countries | JP |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210145079 |
| authorships[2].affiliations[0].raw_affiliation_string | National Cancer Center Hospital East |
| authorships[2].institutions[0].id | https://openalex.org/I4210145079 |
| authorships[2].institutions[0].ror | https://ror.org/03rm3gk43 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210145079 |
| authorships[2].institutions[0].country_code | JP |
| authorships[2].institutions[0].display_name | National Cancer Center Hospital East |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Hirotaka Nakamura |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | National Cancer Center Hospital East |
| authorships[3].author.id | https://openalex.org/A5054157416 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-0979-7998 |
| authorships[3].author.display_name | Satoshi Uchiyama |
| authorships[3].countries | JP |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210145079 |
| authorships[3].affiliations[0].raw_affiliation_string | National Cancer Center Hospital East |
| authorships[3].institutions[0].id | https://openalex.org/I4210145079 |
| authorships[3].institutions[0].ror | https://ror.org/03rm3gk43 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210145079 |
| authorships[3].institutions[0].country_code | JP |
| authorships[3].institutions[0].display_name | National Cancer Center Hospital East |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Satoshi Uchiyama |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | National Cancer Center Hospital East |
| authorships[4].author.id | https://openalex.org/A5081389982 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Kodai Kunisada |
| authorships[4].countries | JP |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210145079 |
| authorships[4].affiliations[0].raw_affiliation_string | National Cancer Center Hospital East |
| authorships[4].institutions[0].id | https://openalex.org/I4210145079 |
| authorships[4].institutions[0].ror | https://ror.org/03rm3gk43 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210145079 |
| authorships[4].institutions[0].country_code | JP |
| authorships[4].institutions[0].display_name | National Cancer Center Hospital East |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Kodai Kunisada |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | National Cancer Center Hospital East |
| authorships[5].author.id | https://openalex.org/A5104281117 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Song‐Gi Chi |
| authorships[5].countries | JP |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210145079 |
| authorships[5].affiliations[0].raw_affiliation_string | National Cancer Center Hospital East |
| authorships[5].institutions[0].id | https://openalex.org/I4210145079 |
| authorships[5].institutions[0].ror | https://ror.org/03rm3gk43 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210145079 |
| authorships[5].institutions[0].country_code | JP |
| authorships[5].institutions[0].display_name | National Cancer Center Hospital East |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Song-Gi Chi |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | National Cancer Center Hospital East |
| authorships[6].author.id | https://openalex.org/A5068037932 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-4202-7554 |
| authorships[6].author.display_name | Akihito Nagata |
| authorships[6].countries | JP |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210145079 |
| authorships[6].affiliations[0].raw_affiliation_string | National Cancer Center Hospital East Nobuhiko Yamauchi National Cancer Center Hospital East Hiraku Ogata National Cancer Center Hospital East Yosuke Minami National Cancer Center Hospital East Junichiro Yuda |
| authorships[6].affiliations[1].institution_ids | https://openalex.org/I4210145079 |
| authorships[6].affiliations[1].raw_affiliation_string | National Cancer Center Hospital East Yong-Mei Guo National Cancer Center Hospital East Hirotaka Nakamura National Cancer Center Hospital East Satoshi Uchiyama National Cancer Center Hospital East Kodai Kunisada National Cancer Center Hospital East Song-Gi Chi National Cancer Center Hospital East |
| authorships[6].affiliations[2].institution_ids | https://openalex.org/I4210145079 |
| authorships[6].affiliations[2].raw_affiliation_string | National Cancer Center Hospital East |
| authorships[6].institutions[0].id | https://openalex.org/I4210145079 |
| authorships[6].institutions[0].ror | https://ror.org/03rm3gk43 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210145079 |
| authorships[6].institutions[0].country_code | JP |
| authorships[6].institutions[0].display_name | National Cancer Center Hospital East |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Akihito Nagata |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | National Cancer Center Hospital East, National Cancer Center Hospital East Nobuhiko Yamauchi National Cancer Center Hospital East Hiraku Ogata National Cancer Center Hospital East Yosuke Minami National Cancer Center Hospital East Junichiro Yuda, National Cancer Center Hospital East Yong-Mei Guo National Cancer Center Hospital East Hirotaka Nakamura National Cancer Center Hospital East Satoshi Uchiyama National Cancer Center Hospital East Kodai Kunisada National Cancer Center Hospital East Song-Gi Chi National Cancer Center Hospital East |
| authorships[7].author.id | https://openalex.org/A5020757111 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-9254-2488 |
| authorships[7].author.display_name | Nobuhiko Yamauchi |
| authorships[7].countries | JP |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210145079 |
| authorships[7].affiliations[0].raw_affiliation_string | National Cancer Center Hospital East |
| authorships[7].institutions[0].id | https://openalex.org/I4210145079 |
| authorships[7].institutions[0].ror | https://ror.org/03rm3gk43 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210145079 |
| authorships[7].institutions[0].country_code | JP |
| authorships[7].institutions[0].display_name | National Cancer Center Hospital East |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Nobuhiko Yamauchi |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | National Cancer Center Hospital East |
| authorships[8].author.id | https://openalex.org/A5101192958 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Hiraku Ogata |
| authorships[8].countries | JP |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210145079 |
| authorships[8].affiliations[0].raw_affiliation_string | National Cancer Center Hospital East |
| authorships[8].institutions[0].id | https://openalex.org/I4210145079 |
| authorships[8].institutions[0].ror | https://ror.org/03rm3gk43 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210145079 |
| authorships[8].institutions[0].country_code | JP |
| authorships[8].institutions[0].display_name | National Cancer Center Hospital East |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Hiraku Ogata |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | National Cancer Center Hospital East |
| authorships[9].author.id | https://openalex.org/A5069675532 |
| authorships[9].author.orcid | https://orcid.org/0000-0003-0863-0739 |
| authorships[9].author.display_name | Yosuke Minami |
| authorships[9].countries | JP |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210145079 |
| authorships[9].affiliations[0].raw_affiliation_string | National Cancer Center Hospital East |
| authorships[9].institutions[0].id | https://openalex.org/I4210145079 |
| authorships[9].institutions[0].ror | https://ror.org/03rm3gk43 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210145079 |
| authorships[9].institutions[0].country_code | JP |
| authorships[9].institutions[0].display_name | National Cancer Center Hospital East |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Yosuke Minami |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | National Cancer Center Hospital East |
| authorships[10].author.id | https://openalex.org/A5089109876 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-4908-1636 |
| authorships[10].author.display_name | Junichiro Yuda |
| authorships[10].countries | JP |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I4210145079 |
| authorships[10].affiliations[0].raw_affiliation_string | National Cancer Center Hospital East |
| authorships[10].institutions[0].id | https://openalex.org/I4210145079 |
| authorships[10].institutions[0].ror | https://ror.org/03rm3gk43 |
| authorships[10].institutions[0].type | healthcare |
| authorships[10].institutions[0].lineage | https://openalex.org/I4210145079 |
| authorships[10].institutions[0].country_code | JP |
| authorships[10].institutions[0].display_name | National Cancer Center Hospital East |
| authorships[10].author_position | last |
| authorships[10].raw_author_name | Junichiro Yuda |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | National Cancer Center Hospital East |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.researchsquare.com/article/rs-3632503/latest.pdf |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Impact of TKI Switching, Reduction, and Discontinuation on Cardiovascular Events in cml patients |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11535 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9973999857902527 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2705 |
| primary_topic.subfield.display_name | Cardiology and Cardiovascular Medicine |
| primary_topic.display_name | Chemotherapy-induced cardiotoxicity and mitigation |
| related_works | https://openalex.org/W2278657325, https://openalex.org/W2991933255, https://openalex.org/W388027184, https://openalex.org/W1915791887, https://openalex.org/W2980430170, https://openalex.org/W2309630174, https://openalex.org/W3194624016, https://openalex.org/W2070391470, https://openalex.org/W2387568071, https://openalex.org/W1984313504 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.21203/rs.3.rs-3632503/v1 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4306402450 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Research Square (Research Square) |
| best_oa_location.source.host_organization | https://openalex.org/I4210096694 |
| best_oa_location.source.host_organization_name | Research Square (United States) |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I4210096694 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.researchsquare.com/article/rs-3632503/latest.pdf |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.21203/rs.3.rs-3632503/v1 |
| primary_location.id | doi:10.21203/rs.3.rs-3632503/v1 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4306402450 |
| primary_location.source.issn | |
| primary_location.source.type | repository |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | |
| primary_location.source.is_core | False |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Research Square (Research Square) |
| primary_location.source.host_organization | https://openalex.org/I4210096694 |
| primary_location.source.host_organization_name | Research Square (United States) |
| primary_location.source.host_organization_lineage | https://openalex.org/I4210096694 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.researchsquare.com/article/rs-3632503/latest.pdf |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.21203/rs.3.rs-3632503/v1 |
| publication_date | 2023-11-26 |
| publication_year | 2023 |
| referenced_works | https://openalex.org/W2397234997, https://openalex.org/W3119368005, https://openalex.org/W2766187515, https://openalex.org/W2260921597, https://openalex.org/W2790692615, https://openalex.org/W2528188718, https://openalex.org/W2976498113, https://openalex.org/W2560342075, https://openalex.org/W2147109509, https://openalex.org/W2099153775, https://openalex.org/W2058216377, https://openalex.org/W1814874339, https://openalex.org/W2258178934, https://openalex.org/W2119010176, https://openalex.org/W2972966208, https://openalex.org/W2043022783, https://openalex.org/W3166015112, https://openalex.org/W3165900016, https://openalex.org/W2039531591, https://openalex.org/W1939978733, https://openalex.org/W2296398034, https://openalex.org/W2428296383, https://openalex.org/W1970293698, https://openalex.org/W2054796764, https://openalex.org/W2323393982, https://openalex.org/W2198866495, https://openalex.org/W3004465995, https://openalex.org/W2288914979, https://openalex.org/W2600212366, https://openalex.org/W2168782870 |
| referenced_works_count | 30 |
| abstract_inverted_index.1 | 82 |
| abstract_inverted_index.a | 200 |
| abstract_inverted_index.16 | 85 |
| abstract_inverted_index.63 | 65 |
| abstract_inverted_index.IM | 217 |
| abstract_inverted_index.No | 122 |
| abstract_inverted_index.QT | 125 |
| abstract_inverted_index.as | 26 |
| abstract_inverted_index.at | 74, 189 |
| abstract_inverted_index.be | 212 |
| abstract_inverted_index.by | 214 |
| abstract_inverted_index.in | 64, 81, 132, 186, 225, 227 |
| abstract_inverted_index.is | 202, 230 |
| abstract_inverted_index.of | 3, 14, 124, 150, 176, 199 |
| abstract_inverted_index.on | 62, 110 |
| abstract_inverted_index.or | 168, 218, 220 |
| abstract_inverted_index.to | 39, 45, 88, 105, 165, 216 |
| abstract_inverted_index.BOS | 219 |
| abstract_inverted_index.CML | 187 |
| abstract_inverted_index.CVE | 177, 209 |
| abstract_inverted_index.DMR | 229 |
| abstract_inverted_index.TKI | 77, 156, 222 |
| abstract_inverted_index.The | 1, 208 |
| abstract_inverted_index.age | 118 |
| abstract_inverted_index.and | 35, 49, 84, 91, 113, 137, 142, 158, 183 |
| abstract_inverted_index.are | 238 |
| abstract_inverted_index.for | 52, 192 |
| abstract_inverted_index.has | 8 |
| abstract_inverted_index.may | 211 |
| abstract_inverted_index.our | 75 |
| abstract_inverted_index.the | 11, 15, 43, 60, 148, 151, 155, 161, 174, 197 |
| abstract_inverted_index.via | 179, 221 |
| abstract_inverted_index.was | 127 |
| abstract_inverted_index.(IM) | 167 |
| abstract_inverted_index.CVE. | 193 |
| abstract_inverted_index.CVEs | 63, 90, 115, 206 |
| abstract_inverted_index.TKI, | 153 |
| abstract_inverted_index.TKIs | 73, 164 |
| abstract_inverted_index.This | 56, 98 |
| abstract_inverted_index.also | 203 |
| abstract_inverted_index.data | 61, 172 |
| abstract_inverted_index.dose | 149, 223 |
| abstract_inverted_index.from | 160 |
| abstract_inverted_index.high | 190 |
| abstract_inverted_index.male | 102 |
| abstract_inverted_index.more | 107, 236 |
| abstract_inverted_index.need | 44 |
| abstract_inverted_index.risk | 191, 210 |
| abstract_inverted_index.same | 152 |
| abstract_inverted_index.such | 25 |
| abstract_inverted_index.than | 95, 119 |
| abstract_inverted_index.that | 101 |
| abstract_inverted_index.were | 79, 144 |
| abstract_inverted_index.when | 205 |
| abstract_inverted_index.whom | 228 |
| abstract_inverted_index.with | 67, 72, 116, 235 |
| abstract_inverted_index.CVEs, | 96 |
| abstract_inverted_index.Rapid | 194 |
| abstract_inverted_index.These | 171 |
| abstract_inverted_index.after | 146 |
| abstract_inverted_index.blood | 180 |
| abstract_inverted_index.brain | 138 |
| abstract_inverted_index.minor | 114 |
| abstract_inverted_index.other | 94 |
| abstract_inverted_index.owing | 87 |
| abstract_inverted_index.phase | 19 |
| abstract_inverted_index.study | 57, 99 |
| abstract_inverted_index.under | 196 |
| abstract_inverted_index.which | 41 |
| abstract_inverted_index.(BOS). | 170 |
| abstract_inverted_index.(TKIs) | 7 |
| abstract_inverted_index.During | 129 |
| abstract_inverted_index.events | 23, 93 |
| abstract_inverted_index.female | 120 |
| abstract_inverted_index.kinase | 5 |
| abstract_inverted_index.occur, | 40 |
| abstract_inverted_index.showed | 100 |
| abstract_inverted_index.tended | 104 |
| abstract_inverted_index.values | 141 |
| abstract_inverted_index.(CVEs), | 24 |
| abstract_inverted_index.adverse | 53, 92 |
| abstract_inverted_index.chronic | 16, 68 |
| abstract_inverted_index.control | 182 |
| abstract_inverted_index.develop | 46 |
| abstract_inverted_index.events. | 55 |
| abstract_inverted_index.further | 233 |
| abstract_inverted_index.myeloid | 69 |
| abstract_inverted_index.patient | 83 |
| abstract_inverted_index.peptide | 140 |
| abstract_inverted_index.serious | 89 |
| abstract_inverted_index.studies | 234 |
| abstract_inverted_index.suggest | 173 |
| abstract_inverted_index.treated | 71 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.However, | 21, 232 |
| abstract_inverted_index.abnormal | 108 |
| abstract_inverted_index.analyzed | 59 |
| abstract_inverted_index.arterial | 29, 33 |
| abstract_inverted_index.cerebral | 36 |
| abstract_inverted_index.continue | 38 |
| abstract_inverted_index.develop. | 207 |
| abstract_inverted_index.disease, | 31 |
| abstract_inverted_index.findings | 109 |
| abstract_inverted_index.gradient | 136 |
| abstract_inverted_index.imatinib | 166 |
| abstract_inverted_index.improved | 10 |
| abstract_inverted_index.interval | 126 |
| abstract_inverted_index.leukemia | 70 |
| abstract_inverted_index.observed | 145 |
| abstract_inverted_index.outcomes | 13 |
| abstract_inverted_index.patients | 66, 86, 103, 188, 226, 237 |
| abstract_inverted_index.pressure | 135, 181 |
| abstract_inverted_index.reducing | 147 |
| abstract_inverted_index.strategy | 51 |
| abstract_inverted_index.tyrosine | 4 |
| abstract_inverted_index.vascular | 54 |
| abstract_inverted_index.(CML-CP). | 20 |
| abstract_inverted_index.achieved. | 231 |
| abstract_inverted_index.bosutinib | 169 |
| abstract_inverted_index.decreased | 213 |
| abstract_inverted_index.essential | 204 |
| abstract_inverted_index.observed. | 128 |
| abstract_inverted_index.occlusive | 30 |
| abstract_inverted_index.patients. | 121 |
| abstract_inverted_index.pulmonary | 32 |
| abstract_inverted_index.required. | 239 |
| abstract_inverted_index.switching | 159, 215 |
| abstract_inverted_index.treatment | 12, 50 |
| abstract_inverted_index.tricuspid | 133 |
| abstract_inverted_index.experience | 106 |
| abstract_inverted_index.follow-up, | 130 |
| abstract_inverted_index.highlights | 42 |
| abstract_inverted_index.importance | 175 |
| abstract_inverted_index.increasing | 117 |
| abstract_inverted_index.inhibitors | 6 |
| abstract_inverted_index.monitoring | 48 |
| abstract_inverted_index.peripheral | 28 |
| abstract_inverted_index.prevention | 178 |
| abstract_inverted_index.preventive | 47 |
| abstract_inverted_index.second-and | 162 |
| abstract_inverted_index.treatment, | 157 |
| abstract_inverted_index.treatments | 78 |
| abstract_inverted_index.cooperation | 198 |
| abstract_inverted_index.development | 2 |
| abstract_inverted_index.examination | 112, 185 |
| abstract_inverted_index.infarction, | 37 |
| abstract_inverted_index.myelogenous | 17 |
| abstract_inverted_index.natriuretic | 139 |
| abstract_inverted_index.regurgitant | 134 |
| abstract_inverted_index.cardiologist | 201 |
| abstract_inverted_index.discontinued | 80 |
| abstract_inverted_index.dramatically | 9 |
| abstract_inverted_index.hypertension | 143 |
| abstract_inverted_index.improvements | 131 |
| abstract_inverted_index.institution. | 76 |
| abstract_inverted_index.interrupting | 154 |
| abstract_inverted_index.intervention | 195 |
| abstract_inverted_index.prolongation | 123 |
| abstract_inverted_index.hypertension, | 27, 34 |
| abstract_inverted_index.respectively. | 97 |
| abstract_inverted_index.cardiovascular | 22, 111, 184 |
| abstract_inverted_index.retrospectively | 58 |
| abstract_inverted_index.leukemia-chronic | 18 |
| abstract_inverted_index.third-generation | 163 |
| abstract_inverted_index.reduction/interruption | 224 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 11 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.7900000214576721 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.35707207 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |